Ophthotech

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

Ophthotech obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.

Ophthotech Gets Rights to Gene Therapy for BEST Disease

Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News for Ophthotech Stock (OPHT)